Mika Reiner Meyer

Working in life sciences offers interesting perspectives on exciting technology. Barney Dixon sat down with Cooley’s Mika Reiner Meyer to find out more

How has the past year at Cooley felt from a professional standpoint?

It has been an amazing year. I had heard from colleagues that Cooley was a collaborative and entrepreneurial environment where working together and thinking creatively was encouraged.

I had heard Cooley’s working environment described as one where the teams made no distinction between partners, associates, patent agents, and staff, and Cooley had repeatedly been recognised as one of the Fortune 100 Best Places to Work. But the thought of making a move was daunting. 

I left a 14-year professional relationship with Morrison & Foerster behind, and now, looking back a year a later, I can say that Cooley has exceeded all my expectations.

My colleagues are caring and collaborative, and the work is challenging and exciting. Within a few months of joining, I was fully integrated, working with partners and practice groups from all over the firm.

Are you seeing a lot of exciting technology come through the door from start-ups?

I am fortunate to work in the life sciences sector, where all the technology that comes through the door is exciting. From miniature life-saving implantable devices, to personalised diagnostics and digital health, every week we see a new start-up with a vision to help people live longer or healthier lives. 

Cooley has a phenomenal emerging company life sciences practice—it is second to none.  It has top-notch lawyers to advise clients across all practice areas, from corporate and licensing to patent and trademark.

The clear synergy with my practice was another motivating factor for me to join Cooley, and I have enjoyed working with my colleagues as part of a complete client team

For start-ups in particular, how are the America Invents Act’s reforms proving today? 

An early concern about the America Invents Act (AIA) was that it would disadvantage small start-ups and independent inventors. The theory was that because smaller companies had fewer resources, they might not be able to file as quickly as larger ones, and thus could potentially lose rights under a first-to-file regime.

I haven’t seen that concern play out in practice. In Silicon Valley, there is a widespread understanding that strong IP protection is a foundation of a company’s success.

Start-ups in the Valley are also fortunate to have incredible resources, such as incubators and mentors to help them identify and pursue key IP.  

The aspect of the AIA that has affected start-ups most in my practice has been the ability to fast-track a patent application through prosecution. For a small fee, patent applicants can expedite prosecution and receive a final decision on patentability from the United States Patent & Trademark Office within 12 months.

This fast-track pathway has been key to start-ups with quick commercial timelines.

Where before a company might be on the market for several years before its patents were issued, now companies can expedite prosecution to better ensure coverage when they are commercial.

Are US patents easier to get than they once were?

I think the different sectors see different cycles. Some patents are easier to get now than others. However, diagnostics and digital health patents have been particularly challenging to get, as the current legal landscape on subject matter eligibility remains somewhat uncertain.

What is the investment view like in life sciences at the moment? Is the patent landscape stable enough to attract investors?

We had a very busy year helping both our venture clients and our company-side clients with respect to financings.
At any given time, we are working on a handful of financings, and it seems like interest in digital health and traditional biotech and pharmaceuticals remains strong.

Even companies that focus on diagnostics (where the patent landscape is somewhat uncertain) often have diverse enough patent portfolios to generate investment interest.

The latest interviews from IPPro Patents
The latest features from IPPro Patents
The European standard-essential patent fight has only just entered round one and with time still on the clock, it’s anyone’s game
The US Court of Appeals for the Federal Circuit’s decision in Aqua Products v the US Patent and Trademark Office has ruffled many feathers, as the burden of proof in an inter-partes review begins to shift to the petitioner
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
Allergan’s recent patent deal with the Saint Regis Mohawk Tribe has drawn the ire of the industry, and the jury is still out on whether it will work
Unfavourable environments for business method patents in the US have led to an increase of filings in Asia. Benjamin Keim of Lee & Hayes explains
Doris Spielthenner of Practice Insight discusses Amazon’s now expired ‘1-Click’ purchase patent and the problems with owning such a broad “super-patent”
While uncertainty persists, plant breeders may need to double down to secure their rights, says Penny Maplestone of the British Society of Plant Breeders
Least developed countries can now more easily obtain compulsory licences during public health emergencies, but some have been slow to take advantage. Vítor Palmela Fidalgo of Inventa International explains why
Diana Portna of D&L IP Group explains how Ukraine’s compulsory licensing laws could be opened up for the public interest, and how rights owners could react
Country profiles
The latest country profiles from IPPro Patents
Bruno Nunes of BN IP explains how patent prosecution and licensing works in Macau, a market dominated by gaming and pharma
Tran Viet Phuong of Duong Tran offers a handy guide to patent prosecution
IPPro Connects

Visit our sister site
the worlds biggest and best IP directory

The Andean Community has stood firm in the defence of its owns interests, says Jesús Cuba and Kelly Sánchez of OMC Abogados & Consultores
The first preliminary injunction granted by a China IP court was awarded to Christian Louboutin. Dr Weili Ma of Chofn Intellectual Property explains
Patent prosecution in South Africa rarely favours the inventor, but recent reforms are aiming to change that, one little bit at a time
The Tanzania Patent Office is a useful partner in the prosecution process, says Sunday Godfrey Ndamugoba of ABC Attorneys
Dominic Ogega Mwale, managing partner at Mwale & Company, explains how to patent in Kenya
Patent owners looking for an attractive place to seek protection in Asia need look no further than Singapore, says Max Ng and Gerald Mursjid of Gateway Law Corporation